A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease

• DOI: 10.1007/s00259-012-2237-2
• Publication Date: 2012-09-07T05:14:23Z
• Authors: Agneta Nordberg; Stephen F. Carter; Juha Rinne; Alexander Drzezga; David J. Brooks; Rik Vandenberghe; Daniela Perani; Anton Forsberg; Bengt Långström; Noora Scheinin; Mira Karrasch; Kjell Någren; Timo Grimmer; Isabelle Miederer; Paul Edison; Aren Okello; Koen Van Laere; Natalie Nelissen; Mathieu Vandenbulcke; Valentina Garibotto; Ove Almkvist; Elke Kalbe; Rainer Hinz; Karl Herholz
• Keywords: Pittsburgh compound B; Apolipoprotein E; Amyloid (mycology)

Amyloid PET tracers have been developed for in vivo detection of brain fibrillar amyloid deposition Alzheimer's disease (AD). To serve as an early biomarker AD the need to be analysed multicentre clinical studies.In this study 238 [(11)C]Pittsburgh compound-B (PIB) datasets from five different European centres were pooled. Of these datasets, 18 excluded, leaving [(11)C]PIB 97 patients with clinically diagnosed (mean age 69 ± 8 years), 72 mild cognitive impairment (MCI; mean 67.5 years) and 51 healthy controls 67.4 6 available analysis. MCI patients, 64 longitudinally followed 28 15 months. Most participants (175 out 220) also tested apolipoprotein E (ApoE) genotype.[(11)C]PIB retention neocortical subcortical regions was significantly higher than age-matched controls. Intermediate observed a bimodal distribution (64 % PIB-positive 36 PIB-negative), which pattern both Higher ApoE ε4 carriers compared non-ApoE (p < 0.005). 67 had converted at follow-up while none PIB-negative converted.This demonstrated robustness marker when assessed setting. showed more severe memory progressed estimated rate 25 per year. None AD, thus PIB negativity 100 negative predictive value progression AD. This supports notion that scans are indicator prodromal